#NovoNordisk's new chief executive, #MikeDoustdar, has told the #JPM2026 Healthcare conference that the key to competing in the #GLP1 agonist category for #weightloss will be to make the most of cash-pay channels.
pharmaphorum.com/news/jpm-nov...
1
0
0
0